The Dutch Protocol Re-Examined

Key Takeaways

• Six adolescents received treatment without formal GD diagnosis
• Only 18% of referred youths did not pursue medical transition
• Hetero-anamnesis omitted from reasons for non-diagnosis
• 28.8% of non‑pursuers later sought treatment as adults
• Intake appears to serve as de‑facto diagnosis

Pulse Analysis

The Dutch Protocol, pioneered at Amsterdam UMC in the 1990s, set the global benchmark for a cautious, staged approach to youth gender dysphoria. By introducing GnRH analogues for puberty suppression followed by cross‑sex hormones and eventual surgery, the model influenced guidelines from the Endocrine Society to WPATH. The new retrospective study, authored by the protocol’s own architects, revisits a decade‑long cohort, revealing that 82% of referred adolescents progressed to medical intervention—a figure that starkly contrasts with the protocol’s advertised conservatism.

Critical scrutiny of the data uncovers several methodological red flags. Six patients began gender‑affirming treatment without a documented DSM‑5‑TR diagnosis, effectively using medication as a diagnostic tool rather than a therapeutic one. Moreover, the study reports an unusually low diagnostic attrition rate after intake, suggesting that the initial assessment functions as the de‑facto diagnosis. The omission of hetero‑anamnesis—a cornerstone of differential diagnosis in earlier Dutch literature—further erodes confidence in the rigor of the evaluation process. These inconsistencies raise concerns about the reproducibility of the protocol’s claimed safeguards.

The implications extend far beyond Amsterdam. Clinics in London, Boston, and Melbourne have modeled their services on the Dutch framework, often citing its evidence‑based reputation. If the foundational study reveals systemic gaps, external audits and transparent reporting become imperative to restore credibility. Stakeholders—including insurers, policymakers, and families—must demand clearer diagnostic criteria, robust attrition tracking, and independent validation before continuing to endorse a model that may no longer meet the highest standards of patient safety and scientific integrity.